Toggle menu
  • Login or Sign Up
  • 0
    • USD
      • British Pound
      • US Dollar
  • Biopharma Research
    Reset Search ×
    • 0
    Reset Search ×
    • USD
      • British Pound
      • US Dollar

      Main Menu

    • OUR SERVICES
      • Custom Research Services
      • Laboratory End User Surveys
    • ABOUT US
    • CONTACT US
    • Shop By Category

    • All Diagnostics Markets
    • PARTNERING, LICENSING, M&A
    • Multiplex Diagnostics
    • Therapeutics
    • Genomics
    • Cancer Diagnostics
    • Infectious Disease Diagnostics
    • COVID-19 Diagnostics
    • Point of Care (POC) Diagnostics
    • Direct-to-Consumer (DTC) Diagnostics
    • Rapid Diagnostics
    • Laboratory Techniques
    • Medical Laboratory Services
    • Calibration
    • USD
      • British Pound
      • US Dollar
    • Gift Certificates
    • Login or Sign Up

    Market ReportsMarket Reports

    Shop by Category

  • All Diagnostics Markets
  • PARTNERING, LICENSING, M&A
  • Multiplex Diagnostics
  • Therapeutics
  • Genomics
  • Cancer Diagnostics
  • Infectious Disease Diagnostics
  • COVID-19 Diagnostics
  • Point of Care (POC) Diagnostics
  • Direct-to-Consumer (DTC) Diagnostics
  • Rapid Diagnostics
  • Laboratory Techniques
  • Medical Laboratory Services
  • Calibration

    • Main Menu

    • OUR SERVICES
      • Custom Research Services
      • Laboratory End User Surveys
    • ABOUT US
    • CONTACT US
    • Shop By Category

    • All Diagnostics Markets
    • PARTNERING, LICENSING, M&A
    • Multiplex Diagnostics
    • Therapeutics
    • Genomics
    • Cancer Diagnostics
    • Infectious Disease Diagnostics
    • COVID-19 Diagnostics
    • Point of Care (POC) Diagnostics
    • Direct-to-Consumer (DTC) Diagnostics
    • Rapid Diagnostics
    • Laboratory Techniques
    • Medical Laboratory Services
    • Calibration
    Reset Search ×
    • 0
    • Home
    • Therapeutics
    • Global Infectious Disease Vaccine Partnering Terms and Agreements 2016-2023
  • Global Infectious Disease Vaccines Partnering Terms and Agreements 2016 to 2023: Deal Trends, Players and Financials
  • Global Infectious Disease Vaccines Partnering Terms and Agreements 2016 to 2023: Deal Trends, Players and Financials
  • Global Infectious Disease Vaccines Partnering Terms and Agreements 2016 to 2023: Deal Trends, Players and Financials
  • Global Infectious Disease Vaccines Partnering Terms and Agreements 2016 to 2023: Deal Trends, Players and Financials Global Infectious Disease Vaccines Partnering Terms and Agreements 2016 to 2023: Deal Trends, Players and Financials Global Infectious Disease Vaccines Partnering Terms and Agreements 2016 to 2023: Deal Trends, Players and Financials

    Global Infectious Disease Vaccine Partnering Terms and Agreements 2016-2023

    $3,995.00
    (You save )
    Write a Review

    SKU:
    CP22061-SU
    Availability:
    Report will be sent the same business day after receipt of cleared payment

    Adding to cart… category.add_cart_announcement

    Share This Article

    • Overview

    Product Description

    Global Infectious Disease Vaccine Partnering Terms and Agreements 2016-2023

    • Publication date: May 2023
    • Page count: 450+
    • Format: Interactive PDF
    • Edition no: 3

    Request a sample

    The Global Infectious Disease Vaccines Partnering Terms and Agreements 2016 to 2023: Deal Trends, Players and Financials report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.  The report also includes adjuvant deals and alliances.

    The report provides the readers with the following key benefits:

    • In-depth understanding of infectious vaccines deal trends since 2016
    • Access to infectious disease vaccines deal headline, upfront, milestone and royalty data
    • Comprehensive access to over 700 links to actual infectious vaccines deals entered into by the world’s biopharma companies, together with real world clause examples
    • Identify leading infectious vaccines deals by value since 2016
    • Identify the most active infectious vaccines dealmakers since 2016
    • Insight into the terms included in infectious vaccines agreement, together with real world clause examples
    • Understand the key deal terms companies have agreed in previous deals          
    • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

    Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not. 

    This report contains a comprehensive listing of all infectious vaccines partnering deals announced since January 2016, including financial terms where available, including over 700 links to online deal records of actual infectious vaccines partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

    The available deals are listed by:

    • Company A-Z
    • Headline value
    • Stage of development at signing
    • Deal component type
    • Specific infectious therapy target

    The initial chapters of this report provide an orientation of infectious vaccines dealmaking and business activities.

    Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in infectious vaccines dealmaking since 2016, including details of average headline, upfront, milestone and royalty terms. Infectious vaccines deals since 2016. Deals are listed by headline value, signed by big pharma, most active infectious vaccines dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

    Chapter 3 provides a review of the leading infectious vaccines deals since 2016. Deals are listed by headline value, signed by big pharma, most active infectious vaccines dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

    Chapter 4 provides a comprehensive listing of the top 25 most active companies in infectious vaccines dealmaking with a brief summary followed by a comprehensive listing of infectious vaccines deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

    Chapter 5 provides a comprehensive and detailed review of infectious vaccines partnering deals signed and announced since Jan 2016, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

    Chapter 6 provides a comprehensive and detailed review of infectious vaccines partnering deals signed and announced since Jan 2016. The chapter is organized by specific infectious vaccines technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

    In addition, a comprehensive appendix is provided organized by infectious vaccines partnering company A-Z, deal type definitions and infectious vaccines partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in infectious vaccines partnering and dealmaking since Jan 2016.

    In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of infectious vaccines technologies and products. 

    Report scope

    Global Infectious Disease Vaccines Partnering Terms and Agreements 2016 to 2023: Deal Trends, Players and Financials is intended to provide the reader with an in-depth understanding and access to infectious vaccines trends and structure of deals entered into by leading companies worldwide.

    The report includes: 

    • Trends in infectious disease vaccines dealmaking in the biopharma industry since 2016
    • Access to headline, upfront, milestone and royalty data
    • Access to over 700 infectious vaccines deal records
    • Identify the most active infectious vaccine dealmakers since 2016
    • The leading infectious vaccines deals by value since 2016
    • Adjuvant deals and alliances since 2016

    In this report, the available deals are listed by:

    • Company A-Z
    • Headline value
    • Stage of development at signing
    • Deal component type
    • Specific infectious therapy target

    Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

    Analyzing actual contract agreements allows assessment of the following:

    • What are the precise rights granted or optioned?
    • What is actually granted by the agreement to the partner company?
    • What exclusivity is granted?
    • What is the payment structure for the deal?
    • How are sales and payments audited?
    • What is the deal term?
    • How are the key terms of the agreement defined?
    • How are IPRs handled and owned?
    • Who is responsible for commercialization?
    • Who is responsible for development, supply, and manufacture?
    • How is confidentiality and publication managed?
    • How are disputes to be resolved?
    • Under what conditions can the deal be terminated?
    • What happens when there is a change of ownership?
    • What sublicensing and subcontracting provisions have been agreed?
    • Which boilerplate clauses does the company insist upon?
    • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
    • Which jurisdiction does the company insist upon for agreement law?

    Product Videos

    Custom Field

    Product Reviews

    Write a Review

    Write a Review

    ×
    Global Infectious Disease Vaccines Partnering Terms and Agreements 2016 to 2023: Deal Trends, Players and Financials
    Global Infectious Disease Vaccine Partnering Terms and Agreements 2016-2023
    ×
    • Recommended
    • You May Also Like
    Global Precision Medicine Partnering Terms and Agreements 2016 to 2023 - Deal Trends, Players and Financials Global Precision Medicine Partnering Terms and Agreements 2016 to 2023 - Deal Trends, Players and Financials
    Quick view

    Global Precision Medicine Partnering Terms and Agreements 2016-2023

    $3,995.00 - $9,995.00
    Choose Options
    Oncology Partnering 2016 to 2023: Deal Terms, Players and Financials Oncology Partnering 2016 to 2023: Deal Terms, Players and Financials
    Quick view

    Oncology Partnering 2016 to 2023: Deal Terms, Players and Financials

    $3,995.00 - $9,995.00
    Choose Options
    Global Diagnostics Partnering Terms and Agreements 2016 to 2023 Global Diagnostics Partnering Terms and Agreements 2016 to 2023
    Quick view

    Global Diagnostics Partnering Terms and Agreements 2016-2023

    $3,995.00 - $9,995.00
    Choose Options
    Companion Diagnostics (CDx) Partnering by Deal Type Global Companion Diagnostics (CDx) Partnering Terms and Agreements 2010 to 2023
    Quick view

    Global Companion Diagnostics Partnering Terms and Agreements 2010-2023

    $3,995.00 - $9,995.00
    Choose Options
    Top Antibody Deals by Deal Type Global Antibody Partnering Terms and Agreements 2016 to 2023
    Quick view

    Global Antibody Partnering Terms and Agreements 2016-2023

    $3,995.00 - $9,995.00
    Choose Options
    Global Precision Medicine Partnering Terms and Agreements 2016 to 2023 - Deal Trends, Players and Financials Global Precision Medicine Partnering Terms and Agreements 2016 to 2023 - Deal Trends, Players and Financials
    Quick view

    Global Precision Medicine Partnering Terms and Agreements 2016-2023

    $3,995.00 - $9,995.00
    Choose Options
    Oncology Partnering 2016 to 2023: Deal Terms, Players and Financials Oncology Partnering 2016 to 2023: Deal Terms, Players and Financials
    Quick view

    Oncology Partnering 2016 to 2023: Deal Terms, Players and Financials

    $3,995.00 - $9,995.00
    Choose Options
    Global Diagnostics Partnering Terms and Agreements 2016 to 2023 Global Diagnostics Partnering Terms and Agreements 2016 to 2023
    Quick view

    Global Diagnostics Partnering Terms and Agreements 2016-2023

    $3,995.00 - $9,995.00
    Choose Options
    Companion Diagnostics (CDx) Partnering by Deal Type Global Companion Diagnostics (CDx) Partnering Terms and Agreements 2010 to 2023
    Quick view

    Global Companion Diagnostics Partnering Terms and Agreements 2010-2023

    $3,995.00 - $9,995.00
    Choose Options
    Latent TB Diagnostics Markets 2023 to 2027
    Quick view

    Latent TB Diagnostics: Global Market Analysis and Forecasts by Assay, Risk Factor and Lab/Place with Executive and Consultant Guides 2023 to 2027

    $6,995.00 - $13,995.00
    Choose Options
    Metagenomic Markets 2023 to 2027
    Quick view

    Metagenomics Markets: Global Market Analysis with Forecasts by Applications, Technologies, Product and User with Executive and Consultant Guides 2023 to 2027

    $6,995.00 - $13,995.00
    Choose Options
    Clinical Laboratory Molecular Diagnostics for Infectious Disease Markets 2023 to 2027
    Quick view

    CLINICAL LABORATORY MOLECULAR DIAGNOSTICS FOR INFECTIOUS DISEASE MARKETS: Strategies and Trends, Forecasts by Application and Country with Market Analysis & Executive Guides 2023 to 2027

    $6,995.00 - $13,995.00
    Choose Options
    Smart In Vitro Diagnostics Markets 2023 to 2027
    Quick view

    SMART IN VITRO DIAGNOSTICS: ARTIFICIAL INTELLIGENCE FOR IVD MARKETS BY APPLICATION, TECHNOLOGY AND USER WITH EXECUTIVE AND CONSULTANT GUIDES 2023-2027

    $6,995.00 - $13,995.00
    Choose Options
    Home Diagnostics Markets 2023 to 2027
    Quick view

    HOME DIAGNOSTICS MARKETS: Strategies and Trends, Forecasts by Application, Channel, Technology and Country with Market Analysis and Executive Guides 2023 to 2027

    $6,995.00 - $13,995.00
    Choose Options
    Top Antibody Deals by Deal Type Global Antibody Partnering Terms and Agreements 2016 to 2023
    Quick view

    Global Antibody Partnering Terms and Agreements 2016-2023

    $3,995.00 - $9,995.00
    Choose Options
    • You May Also Like
    • Recommended
    • Global Precision Medicine Partnering Terms and Agreements 2016 to 2023 - Deal Trends, Players and Financials Global Precision Medicine Partnering Terms and Agreements 2016 to 2023 - Deal Trends, Players and Financials
      Quick view

      Global Precision Medicine Partnering Terms and Agreements 2016-2023

      $3,995.00 - $9,995.00
      Choose Options
    • Oncology Partnering 2016 to 2023: Deal Terms, Players and Financials Oncology Partnering 2016 to 2023: Deal Terms, Players and Financials
      Quick view

      Oncology Partnering 2016 to 2023: Deal Terms, Players and Financials

      $3,995.00 - $9,995.00
      Choose Options
    • Global Diagnostics Partnering Terms and Agreements 2016 to 2023 Global Diagnostics Partnering Terms and Agreements 2016 to 2023
      Quick view

      Global Diagnostics Partnering Terms and Agreements 2016-2023

      $3,995.00 - $9,995.00
      Choose Options
    • Companion Diagnostics (CDx) Partnering by Deal Type Global Companion Diagnostics (CDx) Partnering Terms and Agreements 2010 to 2023
      Quick view

      Global Companion Diagnostics Partnering Terms and Agreements 2010-2023

      $3,995.00 - $9,995.00
      Choose Options
    • Latent TB Diagnostics Markets 2023 to 2027
      Quick view

      Latent TB Diagnostics: Global Market Analysis and Forecasts by Assay, Risk Factor and Lab/Place with Executive and Consultant Guides 2023 to 2027

      $6,995.00 - $13,995.00
      Choose Options
    • Metagenomic Markets 2023 to 2027
      Quick view

      Metagenomics Markets: Global Market Analysis with Forecasts by Applications, Technologies, Product and User with Executive and Consultant Guides 2023 to 2027

      $6,995.00 - $13,995.00
      Choose Options
    • Clinical Laboratory Molecular Diagnostics for Infectious Disease Markets 2023 to 2027
      Quick view

      CLINICAL LABORATORY MOLECULAR DIAGNOSTICS FOR INFECTIOUS DISEASE MARKETS: Strategies and Trends, Forecasts by Application and Country with Market Analysis & Executive Guides 2023 to 2027

      $6,995.00 - $13,995.00
      Choose Options
    • Smart In Vitro Diagnostics Markets 2023 to 2027
      Quick view

      SMART IN VITRO DIAGNOSTICS: ARTIFICIAL INTELLIGENCE FOR IVD MARKETS BY APPLICATION, TECHNOLOGY AND USER WITH EXECUTIVE AND CONSULTANT GUIDES 2023-2027

      $6,995.00 - $13,995.00
      Choose Options
    • Home Diagnostics Markets 2023 to 2027
      Quick view

      HOME DIAGNOSTICS MARKETS: Strategies and Trends, Forecasts by Application, Channel, Technology and Country with Market Analysis and Executive Guides 2023 to 2027

      $6,995.00 - $13,995.00
      Choose Options
    • Top Antibody Deals by Deal Type Global Antibody Partnering Terms and Agreements 2016 to 2023
      Quick view

      Global Antibody Partnering Terms and Agreements 2016-2023

      $3,995.00 - $9,995.00
      Choose Options
    • Global Precision Medicine Partnering Terms and Agreements 2016 to 2023 - Deal Trends, Players and Financials Global Precision Medicine Partnering Terms and Agreements 2016 to 2023 - Deal Trends, Players and Financials
      Quick view

      Global Precision Medicine Partnering Terms and Agreements 2016-2023

      $3,995.00 - $9,995.00
      Choose Options
    • Oncology Partnering 2016 to 2023: Deal Terms, Players and Financials Oncology Partnering 2016 to 2023: Deal Terms, Players and Financials
      Quick view

      Oncology Partnering 2016 to 2023: Deal Terms, Players and Financials

      $3,995.00 - $9,995.00
      Choose Options
    • Global Diagnostics Partnering Terms and Agreements 2016 to 2023 Global Diagnostics Partnering Terms and Agreements 2016 to 2023
      Quick view

      Global Diagnostics Partnering Terms and Agreements 2016-2023

      $3,995.00 - $9,995.00
      Choose Options
    • Companion Diagnostics (CDx) Partnering by Deal Type Global Companion Diagnostics (CDx) Partnering Terms and Agreements 2010 to 2023
      Quick view

      Global Companion Diagnostics Partnering Terms and Agreements 2010-2023

      $3,995.00 - $9,995.00
      Choose Options
    • Top Antibody Deals by Deal Type Global Antibody Partnering Terms and Agreements 2016 to 2023
      Quick view

      Global Antibody Partnering Terms and Agreements 2016-2023

      $3,995.00 - $9,995.00
      Choose Options
    ×
    Contact Us
    Westfield House
    Millfield Lane
    Nether Poppleton
    YORK, YO26 6GA
    United Kingdom
    +44(0)1904 868857
    Accounts & Orders
    • Login or Sign Up
    • Order Status
    • Privacy Security Shipping
    Navigate
    • OUR SERVICES
    • ABOUT US
    • CONTACT US
    Join Our Mailing List

    Sign up for our newsletter to receive specials and up to date product news and releases.

    • © Biopharma Research Ltd